Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
Xīn Gào(Qingdao University), Daniel P. Petrylak(Yale University), Cora N. Sternberg(Cornell University), Richard Gedrich(Arvinas (United States)), Arash Rezazadeh Kalebasty(University of California, Irvine), Ivor Percent(Florida Cancer Specialists & Research Institute), Sunil Gandhi(Florida Cancer Specialists & Research Institute), Guillermo Abesada‐Terk(Florida Cancer Specialists & Research Institute), Maha Hussain(Northwestern University), S. Debbie Chirnomas(Arvinas (United States)), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Howard A. Burris(Deaconess Hospital), Oliver Sartor(Mayo Clinic), Haolan Lu, Jacqueline Vuky(Oregon Health & Science University), Elmer Berghorn(Bristol-Myers Squibb (United States)), John Shen(University of California, Los Angeles), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Robert Dreicer(University of Virginia), Meredith McKean(Sarah Cannon)
Cited by 192
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k